). Cpt1b mÀ/À mice have increased glucose utilization and are resistant to diet-induced obesity. Here, we show that inhibition of mitochondrial FAO induces FGF21 expression specifically in skeletal muscle. The induction of FGF21 in Cpt1b-deficient muscle is dependent on AMPK and Akt1 signaling but independent of the stress signaling pathways. FGF21 appears to act in a paracrine manner to increase glucose uptake under low insulin conditions, but it does not contribute to the resistance to diet-induced obesity.
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In Brief Vandanmagsar et al. show that inhibition of mitochondrial fatty acid oxidation in muscle results in a local increase in FGF21 that is dependent on AMPK and Akt1 signaling but independent of the stress signaling pathways. FGF21 acts in a paracrine manner to increase glucose uptake in muscle.
INTRODUCTION
Fat contributes 90% of the substrate for resting energy expenditure in skeletal muscle and remains the primary fuel during daily activities and low exercise intensities (<40% VO 2 max) (Brooks, 1997; Brooks and Mercier, 1994; Dagenais et al., 1976; Kelley et al., 1993) . Carnitine palmitoyltransferase-1 (CPT1) is located on the outer mitochondrial membrane and transports long-chain fatty acids into mitochondria for b-oxidation. We created a mouse model of impaired fatty acid oxidation (FAO) by deleting CPT1b in skeletal muscle (Cpt1b mÀ/À ) and reported that inhibition of mitochondrial FAO leads to activation of AMPK and PGC1a, resulting in adaptive metabolic responses in skeletal muscle with increased mitochondrial biogenesis, oxidative capacity, compensatory peroxisomal fat oxidation, and amino acid catabolism (Wicks et al., 2015) . In addition, despite elevated plasma lipids and accumulation of both intramyocellular lipids and lipotoxic species, fasting insulin and glucose are lower in Cpt1b mÀ/À mice, with enhanced glucose utilization in Cpt1b mÀ/À mice.
Here we report what appears to be a local starvation response in which FGF21 is specifically upregulated in skeletal muscle of Cpt1b mÀ/À mice.
FGF21 was identified as a novel member of the FGF family that is highly expressed in liver (Nishimura et al., 2000) . FGF21 was subsequently shown to be a potent metabolic regulator of glucose uptake in adipocytes (Kharitonenkov et al., 2005) and is generally thought of as a secreted protein produced by liver in response to starvation (Badman et al., 2007; Inagaki et al., 2007) . However, under myopathic conditions resulting from deficiencies in the mitochondrial respiratory chain, FGF21 can be secreted from skeletal muscle (Kim et al., 2013b; Tyynismaa et al., 2010) . In addition, the transgenic overexpression of Akt1 (Izumiya et al., 2008) , perilipin 5 (Harris et al., 2015) , and UCP1 (Keipert et al., 2014; Ost et al., 2015) in skeletal muscle induces FGF21 secretion. The skeletal muscle-specific ablation of autophagy-related 7 leads to an autophagy deficiency and mitochondrial dysfunction and increases FGF21 in muscle (Kim et al., 2013b; Tyynismaa et al., 2010) . In addition, the skeletal muscle-specific ablation of tuberous sclerosis complex (Tsc) 1, causing activation of mTORC1, induces FGF21 secretion from muscle (Guridi et al., 2015) . A common link among these mouse models (except Akt1 overexpression) is metabolic dysfunction, endoplasmic reticulum (ER) stress, and activation of activating transcription factor 4 (Atf4) as a master regulator of the integrative stress response leading to FGF21 induction.
In the present study, we address whether upregulation of FGF21 in skeletal muscle contributes to the enhanced carbohydrate metabolism (improved insulin sensitivity and glucose utilization) in response to inhibition of mitochondrial FAO in Cpt1b mÀ/À mice. We demonstrate that FGF21 can be upregulated by restricting FAO in muscle in an AMPK-Akt1-dependent manner without activation of the integrative stress response. We also determine the role of FGF21 in the overall phenotype of Cpt1b mÀ/À mice using CPT1b and FGF21 double knockout mice (DKO).
RESULTS

Mitochondrial FAO Deficiency in Muscle Induces FGF21
Serum FGF21 levels were significantly higher in both fed and fasted states in Cpt1b mÀ/À mice compared to control mice ( Figure 1A ). To determine whether increased FGF21 in circulation was arising partly from skeletal muscle, we examined Fgf21 gene expression in several tissues. The mRNA expression of Fgf21 was markedly upregulated in several muscles of Cpt1b mÀ/À mice compared to Cpt1b fl/fl mice, without changes in liver or white adipose tissue (WAT) ( Figure 1B) .
We next evaluated the effect of muscle-specific upregulation of FGF21 on glucose uptake in skeletal muscle. Gene expression of Fgfr1 and its spliced variants Fgfr1b and Fgfr1c were not different in skeletal muscle between Cpt1b mÀ/À and control mice (Figures S1A-S1C). However, proteomic (Wicks et al., 2015) and immunoblot analyses of muscle from Cpt1b mÀ/À mice revealed significantly elevated protein expression of b-Klotho in muscle, which is the essential co-receptor for FGF21 (Figure 1C ) (Ogawa et al., 2007) . Consistent with reports that FGF21 increases glucose uptake via glucose transporter 1 (Glut1) (Kharitonenkov et al., 2005; Mashili et al., 2011) , protein expression of Glut1 was markedly increased in muscle of Cpt1b mÀ/À mice compared to controls ( Figure 1C ). Primary myotubes from Cpt1b mÀ/À mice have a metabolic gene expression profile similar to that in muscle from Cpt1b mÀ/À mice (Figures S1D and S1E). We found significantly increased mRNA expression and protein secretion of FGF21 in primary myotubes derived from Cpt1b mÀ/À mice compared to Cpt1b fl/fl mice ( Figures   1D and 1E ). Basal glucose uptake was significantly elevated in primary myotubes from Cpt1b mÀ/À mice; however, insulin-stimulated glucose uptake was comparable to Cpt1b fl/fl mice (Figure 1F) . FGF21 treatment significantly increased glucose uptake in myotubes from both Cpt1b mÀ/À and control mice, suggesting the elevated basal glucose uptake in myotubes from Cpt1b mÀ/À mice is potentially a result from enhanced FGF21 production ( Figure 1G ).
Insulin Sensitivity in Cpt1b-Deficient Muscle Is Maintained through mTOR-Akt Signaling To determine the underlying molecular mechanisms of increased glucose utilization despite lipotoxity in Cpt1b mÀ/À mice, we first examined the mTOR signaling pathway, which senses nutrient and energy levels and integrates upstream and downstream signals, including growth factors such as insulin (Wullschleger et al., 2006) . Phosphorylation of mTOR at Ser2448, the site associated with mTORC1 activity (Chiang and Abraham, 2005) , was significantly decreased in muscle of Cpt1b mÀ/À mice compared to Cpt1b fl/fl mice ( Figure 2A ). Likewise, phosphorylation of P70 isoform of S6K1, the main downstream effector of mTORC1 (Wullschleger et al., 2006) , was significantly reduced in skeletal muscle from Cpt1b mÀ/À mice ( Figure 2B ). Activation of mTORC1 negatively regulates insulin sensitivity via activation of S6K1, which inhibits IRS protein responsiveness to insulin stimulation by directly phosphorylating IRS1 at Ser636/639 (Um et al., 2004; Wullschleger et al., 2006) . In Cpt1b mÀ/À skeletal muscle, serine phosphorylation of IRS1 was significantly decreased, suggesting reduced mTORC1 signaling ( Figure 2B ). In addition, tyrosine phosphorylation of IRS1, which facilitates insulin responsiveness (Copps and White, 2012) , is significantly increased in skeletal muscle of Cpt1b mÀ/À mice compared to control mice (Figure S2A) . As a consequence of decreased inhibitory action of mTORC1 signaling in Cpt1b mÀ/À muscle in the basal state, we detected significant reductions in basal phosphorylation of both Akt (Ser473) and insulin receptor (IR) (Tyr1162/1163) in skeletal muscle using multiplex and immunoblot analysis (Figures 2C and S2B) . Based upon this evidence we predicted that reduced mTORC1 signaling in the basal state would not only improve basal glucose clearance but also increase sensitivity of Cpt1b mÀ/À muscle to insulin stimulation. Consistent with this, fasting plasma insulin levels were decreased in Cpt1b mÀ/À mice and remained significantly lower throughout life (Wicks et al., 2015) . However, insulin-stimulated phosphorylation of total Akt (Ser473) was comparable between Cpt1b mÀ/À and control mice (Wicks et al., 2015) .
The Akt family includes three members: (1) Akt1 is involved in cellular survival pathways (Chen et al., 2001) , and gene levels were elevated in muscle of Cpt1b mÀ/À mice; (2) Akt2 is an important molecule in the insulin signaling pathway (Garofalo et al., 2003) , but mRNA expression was not different between genotypes; and (3) Akt3 was undetectable in skeletal muscle (Figure 2D) . Phosphorylation of Akt1 (Ser473) at baseline was not different between genotypes, but insulin-stimulated phosphorylation was significantly greater in skeletal muscle of Cpt1b mÀ/À mice ( Figure 2E ). Phosphorylation of Akt2 (Ser474) at baseline was significantly decreased in muscle of Cpt1b mÀ/À mice compared to Cpt1b fl/fl mice, whereas insulin-stimulated Akt2 phosphorylation was comparable between genotypes ( Figure 2F ).
To gain further insight into how impaired mitochondrial FAO causes inhibition of mTORC1 signaling, we next examined upstream factors that affect the mTORC1 pathway. TSC1/TSC2 is a critical regulator of mTOR signaling, and activation of this complex inhibits mTORC1 (Wullschleger et al., 2006) . In contrast, TSC1/TSC2 activates mTORC2, which in turn triggers Akt1 activation (Huang and Manning, 2009) . Within the TSC1/TSC2 complex, TSC1 stabilizes TSC2 (Chong-Kopera et al., 2006) , which facilitates activation of TSC2 by kinases such as AMPK and Akt that directly phosphorylate TSC2 at Ser1387 (Inoki et al., 2003) and Thr1462 (Huang and Manning, 2008) , respectively. We found significantly elevated phosphorylation of TSC2 at Ser1387 in muscle of Cpt1b mÀ/À mice, whereas phosphorylation of TSC2 at Thr1462 was not different. These findings suggest TSC2 activation occurs via AMPK but not Akt in Cpt1b mÀ/À muscle ( Figure 2G ). This is consistent with our previous report that mitochondrial FAO deficiency induced a low-energy state in skeletal muscle of Cpt1b mÀ/À mice that activated AMPK (Wicks et al., 2015) but extends these findings by suggesting that AMPK stimulates the TSC1/TSC2 complex in Cpt1b mÀ/À mice ( Figure 2H ). Specifically, these findings suggest that TSC1/TSC2 inhibits mTORC1 signaling, resulting in enhanced basal insulin sensitivity, and activates the mTORC2 pathway in Cpt1b mÀ/À mice, which increases basal glucose uptake ( Figure 2H ).
Fgf21 Induction in Cpt1b-Deficient Muscle Is AMPK and Akt1 Dependent
Within the model shown in Figure 2H , we predict AMPK and Akt1 signaling are necessary for induction of FGF21 in skeletal muscle of Cpt1b mÀ/À mice. To test this directly, we used mouse and human primary muscle cells. In agreement with our mechanistic hypothesis ( Figure 2H ), expression of Fgf21 in primary myotubes from Cpt1b mÀ/À mice was normalized when exposed to either an Akt1-specific inhibitor, A-674563, or an AMPK inhibitor, compound C ( Figure 3A ). To test whether pharmacological inhibition of CPT1b recapitulates effects of genetic inhibition of Cpt1b, we exposed primary myotubes from Cpt1b fl/fl mice to fatty acid (FA) in the presence of the CPT1 inhibitor, etomoxir. Fgf21 expression was not induced in the presence of FA alone but was robustly elevated in myotubes exposed to FA in the presence of etomoxir in a dose-dependent manner (Figures 3B and S2C) .
To study whether the pharmacological inhibition of CPT1 drives FGF21 induction in the insulin-resistant condition, we explored human skeletal muscle myotubes from diabetic-obese subjects. Our previous report demonstrated that these myotubes are insulin-resistant compared to myotubes derived from non-diabetic-lean (normal-lean) humans (Vandanmagsar et al., 2014) . Treatment with FA induced FGF21 expression in the presence of etomoxir in myotubes from both normal-lean and diabetic-obese subjects; however, FGF21 induction was blunted in myotubes from diabetic-obese subjects ( Figure 3C ). Exposure to A-674563 and compound C blunted FA + etomoxir induction of FGF21 in myotubes from both groups (Ferré , 2004) . FGF21 is induced by PPARa in liver in response to fasting (Inagaki et al., 2007) . However, treatment with inhibitors of PPARa, PPARg, and PPARd did not affect FA + etomoxir-induced FGF21 expression in myotubes from normal-lean subjects (Figure 3D) . Collectively, these data indicate involvement of AMPK and Akt1 signaling in FGF21 induction in the mitochondrial FAO-deficient condition.
To test whether FGF21 directly imparts beneficial effects on the insulin signaling cascade in the presence of excess FA, we treated human myotubes from normal-lean subjects with rhFGF21 ± FA and determined activity of mTOR and its downstream signaling pathways. In the absence of FA, FGF21 had minimal effects, because only phosphorylation of p70S6K was reduced. Alternatively, when FA was present, FGF21 was able to reduce phosphorylation of mTor (Ser2448), p70S6K, IRS1 (Ser636/639), and Akt (Ser473) ( Figure 3E ). Taken together, these data suggest that FGF21 has protective effects on lipid-induced insulin resistance, which in turn preserves glucose uptake in muscle in lipotoxic conditions, such as in skeletal muscle of Cpt1b mÀ/À mice.
Stress Signaling Pathways Are Not Activated by Mitochondrial Fat Oxidation Deficiency
To determine whether other potential signaling pathways lead to induction of FGF21 in skeletal muscle of Cpt1b mÀ/À mice, we evaluated other mechanisms linked to mTOR signaling and FGF21 induction. In Cpt1b mÀ/À mice, systemic and intramyocellular lipids, particularly toxic diacylglycerol (DAG) species, are increased (Wicks et al., 2015) ; thus, DAG signaling could be enhanced. Previous reports have shown that DAG kinases inhibit mTOR activation by repressing Erk1/2 pathways (Gorentla et al., 2011) . Erk1/2 directly phosphorylates TSC2, thus negatively regulating mTORC1 signaling (Ma et al., 2005; Wullschleger et al., 2006) . Phosphorylation of Erk1/2 was not elevated in skeletal muscle of Cpt1b mÀ/À mice ( Figure 4A ). In addition, oxidative stress and hypoxia have been linked to mTORC1 activity (Kim et al., 2002; Wouters and Koritzinsky, 2008) . Gene expression of oxidative stress (Nrf2) and hypoxia (Hif1a) markers was not elevated in muscle of Cpt1b mÀ/À mice compared to Cpt1b fl/fl mice ( Figures 4B and 4C) . Furthermore, the expression levels of ER stress markers (unspliced Xbp1u and spliced Xbp1s) were unchanged in Cpt1b mÀ/À muscle ( Figure 4D ). Moreover, ER stress marker Ddit3 (Haynes and Ron, 2010) expression was significantly decreased in Cpt1b mÀ/À muscle ( Figure 4E ).
In line with these data, Atf4 mRNA and protein expression and Atf5 mRNA expression in skeletal muscle were similar between Cpt1b mÀ/À and Cpt1b fl/fl mice ( Figures 4F and S2D ).
In addition to the candidate gene approach, we did a comprehensive global expression analysis in gastrocnemius muscle from Cpt1b mÀ/À and control mice. The genes belonging to ER stress, autophagy, and mitophagy pathways were obtained from gene ontology and then compared by pathway enrichment analysis by including these three pathways to the standard Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways. None of these overall pathways were significantly different between Cpt1b mÀ/À and Cpt1b fl/fl mice ( Figure 4G) . At the gene level, only 1 gene (Ppp1r15a) out of more than 200 genes was significantly different between Cpt1b mÀ/À and control mice. Heatmaps showing the distribution of expression for genes belonging to these pathways are included in Supplemental Information (Figures S3-S5 ). Moreover, uncoupling protein 3 (Ucp3) expression was significantly increased in Cpt1b mÀ/À muscle ( Figure 4H ), suggesting potential beneficial effects, because it has been reported that upregulated expression of UCP3 reduced ER stress (Xu et al., 2015) and reactive oxygen species (ROS) production (Nabben et al., 2011) . Together, these data indicate that mitochondrial respiratory chain dysfunction and myocellular stress do not appear to be major inducers of FGF21 in Cpt1b mÀ/À muscle and are consistent with our previous report that Cpt1b-deficient mitochondria respire efficiently when given substrates other than long-chain fatty acids (Wicks et al., 2015) . Pathways for oxidative phosphorylation, tricarboxylic acid (TCA) cycle, and overall mitochondrial biogenesis are upregulated in Cpt1b mÀ/À muscle (Wicks et al., 2015) .
Loss of FGF21 Increases Muscle Mass, Activity, Energy Expenditure, and Oxidative Capacity but Does Not Alter Adiposity in Cpt1b mÀ/À Mice
To determine the extent of FGF21's role in the overall phenotype of Cpt1b mÀ/À mice, we generated DKO mice (Fgf21
by crossing Fgf21 À/À mice (Badman et al., 2009; Hotta et al., 2009 ) with Cpt1b mÀ/À mice. As shown in Figure 5A , there was an intermediate effect on body weight in DKO mice. DKO mice were significantly heavier than Cpt1b mÀ/À mice but did not reach the body weight of control or Fgf21 À/À mice ( Figure 5A ). However, there was no difference in fat mass between Cpt1b mÀ/À and DKO mice, as measured by nuclear magnetic resonance (NMR) ( Figure 5B ) or by the weight from individual fat pads ( Figure  5D ). Fat-free mass (FFM) was significantly increased in DKO compared to Cpt1b mÀ/À mice ( Figure 5C ). Gastrocnemius and quadriceps muscles were heavier in both DKO and Fgf21
mice, but liver, kidney, and heart weights were not significantly higher in DKO compared to Cpt1b mÀ/À mice ( Figure 5D ). Body length was significantly decreased in both Cpt1b mÀ/À and DKO mice compared to control mice, whereas Fgf21 À/À mice appeared and Et (100 mM) and PPAR inhibitors GW6471 (for PPARa, 10 mM), T0070907 (for PPARg, 10 mM), and GSK3787 (for PPARd, 10 mM) for 24 hr. *p < 0.05 between treatments with inhibitors and BSA control. (E) Activity of mTORC1 and its downstream signaling members P70S6K, IRS1, and basal Akt, as determined by phosphorylation in human myotubes. HSMMs originating from normal-lean subjects were differentiated into myotubes before treatment with FA (0.5 mM) and rhFGF21 (200 ng/ml). *p < 0.05 between vehicle (PBS) and other treatments. All data are presented as mean ± SEM. All data are presented as mean ± SEM. *p < 0.05, **p < 0.01, and ***p < 0.005 and higher significance.
to have body length significantly longer than that of Cpt1b mÀ/À and DKO mice ( Figure 5E ). Cpt1b mÀ/À mice have reduced activity, leading to an overall decrease in energy expenditure ( Figure 5F ) (Wicks et al., 2015) . The decreased activity in Cpt1b mÀ/À mice is almost restored by the lack of FGF21 in DKO mice with a concomitant increase in energy expenditure ( Figure 5F ). In addition, the respiratory exchange ratio (RER) in DKO mice was comparable to that in control mice ( Figure 5F ). As we previously reported, inhibition of mitochondrial FAO specifically in skeletal muscle results in favorable metabolic adaptations in muscle, such as compensatory increases in carbohydrate oxidation, amino acid oxidation, and peroxisomal fat oxidation (Wicks et al., 2015) . Likewise, we observed increased peroxisomal oxidation of the very long-chain fatty acid lignocerate ( Figure 5G ), enhanced pyruvate dehydrogenase (PDH) activity and pyruvate oxidation through the TCA cycle ( Figure 5H ), and leucine oxidation in skeletal muscle homogenates from Cpt1b mÀ/À mice compared to those from control mice ( Figure 5I ).
The expression of mitochondrial biogenesis genes in muscle of DKO was comparable to the increased level in Cpt1b mÀ/À muscle ( Figure S6A ). Loss of FGF21 had little effect on oxidation, but the combined loss of CPT1b and FGF21 in DKO mice further increased PDH activity and increased pyruvate oxidation through the TCA cycle, leucine oxidation, and peroxisomal oxidation ( Figures 5G-5I ). In summary, overall fat mass is not increased in DKO mice. Rather, elevated FGF21 in Cpt1b mÀ/À mice seems to negatively regulate muscle mass, activity, and energy expenditure. Figure 6A ). Compared to control mice, insulin-stimulated glucose clearance was also improved in Cpt1b mÀ/À mice during an insulin tolerance test (ITT). Similar to the GTT, these improvements in insulin sensitivity were negated in DKO mice compared to Cpt1b mÀ/À mice ( Figure 6B ). Consistent with this, basal phosphorylation of Akt (Ser473) in skeletal muscle of DKO mice was significantly higher compared to Cpt1b mÀ/À muscle, whereas it was significantly lower compared to Fgf21 À/À muscle and was indifferent compared to control mice muscle ( Figure 6C ). However, insulin-stimulated phosphorylation of Akt (Ser473) in muscle of DKO was comparable to levels in control and Cpt1b mÀ/À muscle ( Figure 6D ). Phosphorylation of Akt1 (Ser473) at baseline was not different among all genotypes ( Figure 6E ). However, Akt1 phosphorylation in response to insulin in muscle of DKO mice was similar to Cpt1b mÀ/À muscle and was significantly increased compared to control mice muscle ( Figure 6F ), indicating again that Fgf21 is downstream of Akt1 signaling in Cpt1b-deficient muscle ( Figure 2H ). Reduced phosphorylation of Akt2 (Ser474) at baseline in skeletal muscle of Cpt1b mÀ/À mice was reversed in muscle from DKO mice so that it was comparable to that from control mice ( Figure 6G ), whereas Akt2 phosphorylation in response to insulin was comparable among all genotypes ( Figure 6H ). These data reinforce a possible feedback inhibition of mTORC1 by FGF21, through which FGF21 contributes to enhanced basal insulin sensitivity in Cpt1b Figures 7A, 7B , and S6B). Consistent with previous reports that FGF21 exerts metabolic action enhancing lipolysis, fat oxidation (Coskun et al., 2008) , and accumulation of beige adipocytes in other metabolic tissues (Fisher et al., 2012; Keipert et al., 2014) , expression of Pnpla2, Hadha, and Cs genes was significantly upregulated in WAT of Cpt1b mÀ/À mice compared to control mice, without affecting liver expression ( Figures 7C-7E and S6C ). Collectively, these data are consistent with elevated lipolysis and lipid oxidation in WAT depots but not in liver of Cpt1b mÀ/À mice ( Figures   7C-7E and S6C ). This seems to be at least partially mediated via FGF21, because DKO mice exhibit significantly attenuated gene expression of the lipolytic marker Pnpla2 (Atgl) in WAT of DKO mice compared to Cpt1b mÀ/À mice ( Figure 7C ), as well as reduced expression of fat oxidation markers Hadha and Cs in inguinal WAT (iWAT) of DKO mice ( Figures 7D and 7E ). Alternatively, Hadha and Cs gene expression was similar in epididymal WAT (eWAT) of DKO mice compared to Cpt1b mÀ/À mice ( Figures  7D and 7E) .
In addition, expression of brown adipocyte markers such as Ucp1 and Cidea was significantly increased in iWAT, but not in eWAT, of Cpt1b mÀ/À mice compared to control mice ( Figures   7F and S6D) . Expression of Ucp1 and Cidea was entirely attenuated in iWAT of Fgf21 À/À and DKO mice compared to Cpt1b mÀ/À mice ( Figure 7F ). Given the reversal of FAO enzymes and Ucp1 and Cidea expression by loss of FGF21 in DKO mice, increased fat mass might be expected. However, neither fat mass by NMR ( Figure 5B ) nor individual fat pad weight ( Figure 5D ) were different between DKO mice and Cpt1b mÀ/À mice. In addition, there is an obvious decrease in adipocyte size in Cpt1b mÀ/À mice compared to control mice that is not changed by the loss of FGF21 ( Figure 7G ).
Effects on Liver, Pancreas, IGF-1, and Adiponectin in Cpt1b mÀ/À Mice
The pancreas and liver are both known producers and targets of FGF21 (Fon Tacer et al., 2010) . In Figure 1B , we reported no increase in FGF21 expression in liver of Cpt1b mÀ/À mice. Likewise, the expression of Klb, Fgfr4, and Fgfr1c in liver of Cpt1b mÀ/À mice was unaltered compared to Cpt1b fl/fl mice ( Figures S6E   and S6F ). Expression of Fgfr1b was significantly increased in liver of Cpt1b mÀ/À mice. However, the expression level was negligible compared to expression of other Fgf receptors in liver ( Figure S6F ). In addition, gene expression of Fgf21 and of Klb and Fgf receptors in pancreas was comparable between Cpt1b mÀ/À and Cpt1b fl/fl mice ( Figures S6G and S6H ).
In a transgenic animal model, it has been shown that FGF21-overexpressing mice have significantly lower levels of IGF-1 compared to wild-type mice (Inagaki et al., 2008) . Serum levels of IGF-1 were significantly lower in Cpt1b mÀ/À mice (n = 52-59) ( Figure S7A ). In a smaller cohort, IGF-1 was significantly lower in Cpt1b mÀ/À mice and DKO mice compared to control and Fgf21 À/À mice ( Figure S7B ). These data are consistent with decreased body length in Cpt1b mÀ/À and DKO mice ( Figure 5E ), but they do not suggest that reduced IGF-1 is driven by increased circulating FGF21 in Cpt1b mÀ/À mice. Though the metabolic effect of FGF21 has been shown to be dependent upon adiponectin (Holland et al., 2013) , the expression of adiponectin receptors, Adipor1 and Adipor2, was not different in skeletal muscle between Cpt1b mÀ/À and Cpt1b fl/fl mice ( Figures S6C   and S6D ). Serum levels of total and high molecular weight adiponectin were also similar between Cpt1b mÀ/À and Cpt1b fl/fl mice ( Figures S6E and S6F ). This is consistent with a paper (Kolumam et al., 2015) demonstrating FGF21 mimetic antibody has metabolic effects in adiponectin-knockout mice.
DISCUSSION
Previously, we showed that AMPK/PGC1a activated by energy deprivation orchestrates compensatory increases in mitochondrial biogenesis, mitochondrial oxidative capacity, fat oxidation by peroxisomes, and usage of amino acids as energy sources in Cpt1b mÀ/À muscle (Wicks et al., 2015) . Here we show that AMPK, through activation of the TSC complex, (1) activates mTORC2-Akt1-FGF21, leading to an increase in Glut1, and (2) inactivates mTORC1-S6K-IRS-1 serine phosphorylation. Both stimulate glucose uptake at low insulin levels. The induction of FGF21 in response to impaired mitochondrial FAO in skeletal muscle is a part of several compensatory adaptations designed to maintain energy supply to muscle in Cpt1b mÀ/À mice. While liver is considered the major organ for the upregulation and secretion of FGF21 in an energy-or nutrient-deficient state, muscle has also been shown to secrete FGF21. Energy deficit caused by respiratory chain deficiencies leads to mitochondrial myopathy and increased FGF21 production in mice and humans (Suomalainen et al., 2011; Tyynismaa et al., 2010) . In another model of mitochondrial inefficiency, muscle-specific overexpression of UCP-1 causes FGF21 upregulation in skeletal muscle (Keipert et al., 2014; Ost et al., 2015) . Dysregulation of lipid delivery to mitochondria by either overexpression of perilipin 5 (Harris et al., 2015) or deletion of the lipase ATGL (Brahma et al., 2014) , leads to FGF21 induction in skeletal muscle or heart, respectively. Taken together with our data, these results suggest that many pathophysiological conditions (disorders of lipid uptake and transport, lipid droplet formation and lipolysis, any defect in the carnitine shuttle system, disorders of mitochondrial FAO, and mitochondrial dysfunction) stimulate FGF21 production in muscle.
All preceding models represent rather severe conditions that identified specific pathways for FGF21 regulation in muscle. While still not physiological, one study demonstrated that after a prolonged 3-4 hr hyperinsulinemic-euglycemic clamp, both skeletal muscle FGF21 mRNA and circulating FGF21 were increased (Hojman et al., 2009) . The hyperinsulinemic-euglycemic clamp procedure can be considered a period of suppression of FAO. In the present study, we demonstrate that there is minimal FGF21 expression in murine or human primary myotubes and that incubation of either murine or human primary myotubes with a palmitate-oleate mixture or the CPT1 inhibitor etomoxir alone has no effect on FGF21 mRNA. However, the combination of fatty acids and etomoxir increases FGF21 expression nearly 10-fold ( Figures 3A-3C ). We also demonstrate that FGF21 induction is blunted in differentiated myotubes from obese-diabetic subjects. Moreover, we observe decreased mitochondrial FAO induces FGF21 in otherwise ''healthy'' myotubes. We also demonstrate that the regulation of FGF21 production appears to be mediated through an AMPK-mTOR-Akt1 axis ( Figures  3A-3C ). This is in agreement with a transgenic mouse model, in which overexpression of Akt1 induces FGF21 secretion from muscle (Izumiya et al., 2008) . Two previous studies report beneficial effects of FGF21 treatment on human myotubes by increasing glucose uptake (Mashili et al., 2011) and suppressing necrosis factor kB (Lee et al., 2012) . We further show that FGF21 has beneficial effects in human myotubes. FGF21 was able to repress mTORC1, leading to subsequent repression of IRS1 phosphorylation at Ser636/639 and improved downstream insulin signaling in the presence of FA. Numerous studies demonstrate that the induction of FGF21 requires an ATF4-dependent mechanism (De Sousa-Coelho et al., 2012; Kim et al., 2013a; Kim et al., 2013b; Ost et al., 2015; Tyynismaa et al., 2010) . We were surprised to see no changes in Atf4 mRNA or protein levels in Cpt1b mÀ/À mice. In addition, markers for oxidative stress (Nrf2), hypoxia (Hif1a), and ER stress (unspliced Xbp1u and spliced Xbp1s, Ddit3) were not elevated in Cpt1b mÀ/À muscle (Figure 4 ). In addition,
a comprehensive global expression analysis demonstrated that ER stress, autophagy, and mitophagy pathways are not significantly different between Cpt1b mÀ/À and control mice ( Figures   S3-S5) . Despite the accumulation of total lipid and lipotoxic intermediates, the skeletal muscle from Cpt1b mÀ/À mice has characteristics similar to that from trained athletes (Goodpaster et al., 2001) , including increased glucose and lipid uptake, large lipid droplets, increased mitochondrial biogenesis, and increased mitochondrial oxidative capacity, although Cpt1b mÀ/À mice are hypoactive (Wicks et al., 2015) .
When we investigated the role of muscle-derived FGF21 in the obesity-resistant phenotype in Cpt1b mÀ/À mice at the wholebody level (see Figure 7H for summary), DKO mice showed a modest attenuation in the body weight reduction observed in Cpt1b mÀ/À mice. However, the increase in body weight between Cpt1b mÀ/À and DKO mice was entirely accounted for by an increase in FFM in DKO mice. The decreased fat mass and body length observed in Cpt1b mÀ/À mice was not corrected by the absence of FGF21. Examination of individual tissues again shows that the reduced fat mass in Cpt1b mÀ/À mice is not increased in DKO mice. Likewise, the mass of major organs, such as liver, heart, and kidney, is still reduced in DKO mice. We did observe an increase in skeletal muscle mass in both Fgf21 À/À and DKO mice, which is probably responsible for the increased FFM. The reduced spontaneous activity observed in Cpt1b mÀ/À mice is normalized in DKO mice. The increased activity may be supported by the increased muscle mass rather than the known effects of FGF21 on torpor and circadian rhythms (Bookout et al., 2013) , because activity in Fgf21 À/À mice is not greater than that in control mice ( Figure 5 ). The improved glucose uptake during a GTT was partially blunted in DKO mice, and the marginal decrease in blood glucose during an ITT was returned to control levels in DKO mice. At the muscle level, the reduced phosphorylation of Akt2 at baseline in Cpt1b mÀ/À muscle was substantially reversed in muscle of DKO mice, indicating that FGF21 contributes largely to the improvement in basal insulin sensitivity in Cpt1b mÀ/À muscle. When we investigated the role of FGF21 in the increased oxidative capacity of Cpt1b mÀ/À muscle, we found that DKO mice showed further increases in peroxisomal fat, carbohydrate, and amino acid oxidation. A potential explanation is that beneficial effects of FGF21 on glucose uptake are gone in DKO mice and that the muscle is further compensating to increase oxidative capacity. FGF21 has been reported to ameliorate diet-induced obesity and insulin resistance by increasing lipolysis and b-oxidation (Coskun et al., 2008; Inagaki et al., 2007; Kharitonenkov et al., 2005) We detected elevated markers of mitochondrial number, lipolysis, b-oxidation, and adipocyte browning in WAT of Cpt1b mÀ/À mice. Moreover, expression of browning markers was reversed in iWAT of DKO mice, reaching levels similar to those in control mice. However, the reversal of browning markers has no effect on fat mass as measured by NMR, mass of individual fat depots, or adipocyte histology, suggesting the level of browning observed in Cpt1b mÀ/À mice is not high enough to increase whole-body energy expenditure. The lack of an effect of FGF21 on adiposity was also observed in the transgenic mice overexpressing UCP-1 in skeletal muscle (Ost et al., 2015) . In summary, the combination of elevated fatty acids and CPT1b inhibition increases FGF21 production in skeletal muscle via an AMPK-mTor-Akt1 pathway. This regulation does not involve induction of the ER stress pathway, which has been reported to be a primary mediator of FGF21 induction in skeletal muscle under pathological conditions. Results from the present study indicate that production of FGF21 in skeletal muscle of Cpt1b mÀ/À mice improves metabolic health, because FGF21 appears to act in a paracrine manner in muscle to improve glucose uptake in these mice. While circulating FGF21 does produce browning in adipose tissue, FGF21 does not drive the obesity-resistant phenotype observed in Cpt1b mÀ/À mice. Further studies are needed to evaluate FGF21-independent pathways in Cpt1b mÀ/À mice that would provide new insights on resistance to diet-induced obesity. Altogether, our findings suggest that pharmacologically targeted CPT1b inhibition specifically in skeletal muscle could trigger favorable adaptive responses, resulting in improved glucose uptake and reduced fat mass, and that the improvements in glucose homeostasis are partially driven by muscle-specific upregulation of FGF21.
EXPERIMENTAL PROCEDURES Animal Studies
Animal studies were conducted at Pennington Biomedical Research Center's American Association for Laboratory Animal Care (AALAC)-approved facility on a standard breeder chow diet, composed of 20% protein, 25% fat, and 55% carbohydrate (Purina Rodent Chow no. 5015, Purina Mills). All experiments were in compliance with the NIH Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee. All mice used in the experiments were 3-4 months old unless specified otherwise.
Animal Procedures
Serum and plasma collections were performed by submandibular bleed. GTTs were performed following a 4-hr fast by intraperitoneal (i.p.) injection of 10% D-glucose (0.68 g/kg body weight). ITTs were done in the fed state using an i.p. dose of 0.04 U/kg body weight. For insulin signaling studies, mice were fasted overnight and then given an i.p. injection of insulin (1.0 U/kg body
